BridgeMD
Phase II: 68Ga-NODAGA-E[c(RGDyK)]2 Angiogenese PET for imaging angiogenesis in ischemic heart disease
EU CTIS ID: 2024-518640-20-00
What this study is testing
Investigate and characterize the difference in myocardial angiogenesis measured with RGD-PET uptake before and after coronary revascularization in patients with chronic ischemic heart disease.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subjects > 50 years old
- Subjects admitted to the Heart Center, Rigshospitalet, with chronic occlusion of coronary arteries and clinically referred for either PCI or CABG.
You likely can't join if
- Subject with a history of heart surgery
- If the subject shows clinical signs of a severe allergic reaction related to intravenous contrast agent or the tracer, the patient will be withdrawn from the study
- If it is discovered during the PET scan that the tracer has been injected subcutaneously, the subject will be withdrawn from the project
- Uncontrolled diabetes type I & II (HbA1c >70)
- Subject receiving strong anti-angiogenic medication such as Avastin ©
- Pregnancy
See the full eligibility criteria
- Subjects > 50 years old
- Subjects admitted to the Heart Center, Rigshospitalet, with chronic occlusion of coronary arteries and clinically referred for either PCI or CABG.
- Subject with a history of heart surgery
- If the subject shows clinical signs of a severe allergic reaction related to intravenous contrast agent or the tracer, the patient will be withdrawn from the study
- If it is discovered during the PET scan that the tracer has been injected subcutaneously, the subject will be withdrawn from the project
- Uncontrolled diabetes type I & II (HbA1c >70)
- Subject receiving strong anti-angiogenic medication such as Avastin ©
- Pregnancy
- Lactation
- Severe claustrophobia to a degree that makes PET/CT scanning impossible
- Severe obesity (>140 kg)
- Re-operation during intervention
- Conversion from PCI to open surgery
- If the subject is of childbearing age, a pregnancy test will be performed prior to the injection of the tracer. If positive, the patient will be excluded from the study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.